Safety and Efficacy of Resolute Zotarolimus-Eluting Stents Compared with Everolimus-Eluting Stents

Circulation: Cardiovascular Interventions

Volumn 8, Issue 4, 2015, Pages

  Piccolo, Raffaele ^a   Stefanini, Giulio G ^a   Franzone, Anna ^a   Spitzer, Ernest ^a   Blöchlinger, Stefan ^a   Heg, Dik ^b,c   Jüni, Peter ^b   Windecker, Stephan ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

everolimus eluting stent; meta analysis; randomized controlled trial; zotarolimus eluting stent

Indexed keywords

ARTICLE; COMPARATIVE STUDY; CORONARY ARTERY RECANALIZATION; DEVICE SAFETY; EVEROLIMUS ELUTING CORONARY STENT; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; META ANALYSIS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STENT THROMBOSIS; SYSTEMATIC REVIEW; ZOTAROLIMUS ELUTING CORONARY STENT; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; DRUG ELUTING STENT; MORTALITY; POSTOPERATIVE COMPLICATION; SURVIVAL ANALYSIS; THROMBOSIS; TREATMENT OUTCOME; UTILIZATION;

EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; ZOTAROLIMUS;

DRUG-ELUTING STENTS; EVEROLIMUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS; SURVIVAL ANALYSIS; THROMBOSIS; TREATMENT OUTCOME;

EID: 84937402993     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.114.002223     Document Type: Article

References (38)

1. Stefanini GG, Holmes DR Jr. Drug-eluting coronary-artery stents. N Engl J Med. 2013;368:254-265. Doi: 10. 1056/NEJMra1210816.
2. Wenaweser P, Daemen J, Zwahlen M, van Domburg R, Jüni P, Vaina S, Hellige G, Tsuchida K, Morger C, Boersma E, Kukreja N, Meier B, Serruys PW, Windecker S. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol. 2008;52:1134-1140. Doi: 10. 1016/j. jacc. 2008. 07. 006.
3. Windecker S, Meier B. Late coronary stent thrombosis. Circulation. 2007;116:1952-1965. Doi: 10. 1161/CIRCULATIONAHA. 106. 683995.
4. Windecker S, Jüni P. Safety of drug-eluting stents. Nat Clin Pract Cardiovasc Med. 2008;5:316-328. Doi: 10. 1038/ncpcardio1189.
5. Stefanini GG, Taniwaki M, Windecker S. Coronary stents: novel developments. Heart. 2014;100:1051-1061. Doi: 10. 1136/heartjnl-2012-303522.
6. Windecker S, Stortecky S, Stefanini GG, da Costa BR, Rutjes AW, Di Nisio M, Silletta MG, Maione A, Alfonso F, Clemmensen PM, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head S, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter D, Schauerte P, Sousa Uva M, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A, Kolh P, Jüni P. Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ. 2014;348:g3859.
7. Kang SH, Park KW, Kang DY, Lim WH, Park KT, Han JK, Kang HJ, Koo BK, Oh BH, Park YB, Kandzari DE, Cohen DJ, Hwang SS, Kim HS. Biodegradable-polymer drug-eluting stents vs. Bare metal stents vs. Durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis. Eur Heart J. 2014;35:1147-1158. Doi: 10. 1093/eurheartj/eht570.
8. Navarese EP, Tandjung K, Claessen B, Andreotti F, Kowalewski M, Kandzari DE, Kereiakes DJ, Waksman R, Mauri L, Meredith IT, Finn AV, Kim HS, Kubica J, Suryapranata H, Aprami TM, Di Pasquale G, von Birgelen C, Kedhi E. Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. BMJ. 2013;347:f6530.
9. Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabaté M, Smits PC, Kaiser C, D'Ascenzo F, Frati G, Mancone M, Genereux P, Stone GW. Clinical outcomes with bioabsorbable polymer-versus durable polymerbased drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2014;63:299-307. Doi: 10. 1016/j. jacc. 2013. 09. 061.
10. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-2351. Doi: 10. 1161/ CIRCULATIONAHA. 106. 685313.
11. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med. 2006;25:3443-3457. Doi: 10. 1002/sim. 2380.
12. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295:676-680. Doi: 10. 1001/jama. 295. 6. 676.
13. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol. 2008;61:64-75. Doi: 10. 1016/j. jclinepi. 2007. 03. 013.
14. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
15. Windecker S. Final 5-year report of the RESOLUTE All-Comers Randomised Study. Presented at EuroPCR 2014, Paris (France). http:// www. Pcronline. Com/file/download/(path)/var/www/media/pcronline/ diapos/EuroPCR2014/(id)/4069-20140522-1540-Room-341- Windecker-Stephan-0000-(10653)/(ext)/pdf/(ref)/216677/(filename)/ Windecker-Stephan-20140522-1540-Room-341. Pdf.
16. Löwik MM, Lam MK, Sen H, Tandjung K, van Houwelingen KG, de Man FH, Stoel MG, Louwerenburg JH, Linssen GC, Doggen CJ, von Birgelen C. Safety of second-generation drug-eluting stents three years after randomised use in the TWENTE trial. EuroIntervention. 2015;10:1276-1279. Doi: 10. 4244/EIJY14M08-11.
17. Mehilli J, Richardt G, Valgimigli M, Schulz S, Singh A, Abdel-Wahab M, Tiroch K, Pache J, Hausleiter J, Byrne RA, Ott I, Ibrahim T, Fusaro M, Seyfarth M, Laugwitz KL, Massberg S, Kastrati A; ISAR-LEFT-MAIN 2 Study Investigators. Zotarolimus-versus everolimus-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol. 2013;62:2075-2082. Doi: 10. 1016/j. jacc. 2013. 07. 044.
18. von Birgelen C, Lam MK, Lowik MM, Danse PW, Jessurun GA, Gin RM, Anthonio RL, van Houwelingen GK, de Man FH, Stoel MG, Louwerenburg JH, Hautvast RW, Linssen GC, Hartmann M, Tandjung K, van der Heijden LC, Ijzerman M, Doggen CJ, Sen H. 2-Year Clinical Outcome of the Randomized, Multicenter DUTCH PEERS (TWENTE II) Trial, Comparing Cobalt-Chromium Zotarolimus-Eluting Resolute Integrity Stents and Platinum-Chromium Everolimus-Eluting Promus Element Stents in All-Comer Patients. Presented at TCT 2014, Washington, DC (USA). http://www. Tctmd. Com/show. Aspxid=126060.
19. Park KW, Kang SH, Kang HJ, Koo BK, Park BE, Cha KS, Rhew JY, Jeon HK, Shin ES, Oh JH, Jeong MH, Kim S, Hwang KK, Yoon JH, Lee SY, Park TH, Moon KW, Kwon HM, Hur SH, Ryu JK, Lee BR, Park YW, Chae IH, Kim HS; HOST-ASSURE Investigators. A randomized comparison of platinum chromium-based everolimus-eluting stents versus cobalt chromium-based zotarolimus-eluting stents in all-comers receiving percutaneous coronary intervention: HOST-ASSURE (harmonizing optimal strategy for treatment of coronary artery stenosis-safety & effectiveness of drug-eluting stents & anti-platelet regimen), a randomized, controlled, noninferiority trial. J Am Coll Cardiol. 2014;63(25 pt A):2805-2816. Doi: 10. 1016/j. jacc. 2014. 04. 013.
20. Varenhorst C, Sarno G, Olivecrona G, Tornvall P, Nilsson J, Carlsson J, James S, Largerqvist B. SCAAR: lower late and very late stent thrombosis rates with new generation drug eluting stents compared to bare metal stents. Presented at ESC Congress 2014, Barcelona (Spain). http://spo. escardio. org/Slides. Aspxeevtid=69&ePresId=lATb0ZoX1oU%3D.
21. Sarno G, Lagerqvist B, Fröbert O, Nilsson J, Olivecrona G, Omerovic E, Saleh N, Venetzanos D, James S. Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J. 2012;33:606-613. Doi: 10. 1093/eurheartj/ehr479.
22. Räber L, Magro M, Stefanini GG, Kalesan B, van Domburg RT, Onuma Y, Wenaweser P, Daemen J, Meier B, Jüni P, Serruys PW, Windecker S. Very late coronary stent thrombosis of a newer-generation everolimuseluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation. 2012;125:1110-1121. Doi: 10. 1161/ CIRCULATIONAHA. 111. 058560.
23. Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, DiMario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J, Bressers M, Gobbens P, Negoita M, van Leeuwen F, Windecker S. Comparison of zotarolimus-eluting and everolimuseluting coronary stents. N Engl J Med. 2010;363:136-146. Doi: 10. 1056/ NEJMoa1004130.
24. Taniwaki M, Stefanini GG, Silber S, Richardt G, Vranckx P, Serruys PW, Buszman PE, Kelbaek H, Windecker S; RESOLUTE All-Comers Investigators. 4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention). J Am Coll Cardiol. 2014;63:1617-1625. Doi: 10. 1016/j. jacc. 2013. 12. 036.
25. Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Genereux P, Branzi A, Stone GW. Stent thrombosis with drug-eluting stents: is the paradigm shifting J Am Coll Cardiol. 2013;62:1915-1921. Doi: 10. 1016/j. jacc. 2013. 08. 725.
26. Sen H, Lam MK, Tandjung K, Löwik MM, Stoel MG, de Man FH, Louwerenburg JH, van Houwelingen GK, Linssen GC, Doggen CJ, Basalus MW, von Birgelen C. Complex patients treated with zotarolimuseluting resolute and everolimus-eluting Xience V stents in the randomized TWENTE trial: comparison of 2-year clinical outcome. Catheter Cardiovasc Interv. 2015;85:74-81. Doi: 10. 1002/ccd. 25464.
27. Stefanini GG, Serruys PW, Silber S, Khattab AA, van Geuns RJ, Richardt G, Buszman PE, Kelbak H, van Boven AJ, Hofma SH, Linke, A Klauss V, Wijns W, Macaya C, Garot P, Di Mario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli AL, Gobbens P, Windecker S. The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus-and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention). J Am Coll Cardiol. 2011;57:2221-2232. Doi: 10. 1016/j. jacc. 2011. 01. 036.
28. Zhang XL, Li R, Wu H, Chen QH, Li GN, Xie J, Xu B. Head-to-head comparison of everolimus-eluting stents versus zotarolimus-eluting stents in patients undergoing percutaneous coronary intervention: a meta-analysis. Int J Cardiol. 2014;172:e203-e206. Doi: 10. 1016/j. ijcard. 2013. 12. 153.
29. Park KW, Lee JM, Kang SH, Ahn HS, Kang HJ, Koo BK, Rhew JY, Hwang SH, Lee SY, Kang TS, Kwak CH, Hong BK, Yu CW, Seong IW, Ahn T, Lee HC, Lim SW, Kim HS. Everolimus-eluting Xience v/ Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus. JACC Cardiovasc Interv. 2014;7:471-481. Doi: 10. 1016/j. jcin. 2013. 12. 201.
30. Yazdani SK, Sheehy A, Nakano M, Nakazawa G, Vorpahl M, Otsuka F, Donn RS, Perkins LE, Simonton CA, Kolodgie FD, Virmani R. Preclinical evaluation of second-generation everolimus-and zotarolimus-eluting coronary stents. J Invasive Cardiol. 2013;25:383-390.
31. Gutiérrez-Chico JL, van Geuns RJ, Regar E, van der Giessen WJ, Kelbak H, Saunamäki K, Escaned J, Gonzalo N, di Mario C, Borgia F, Nüesch E, García-García HM, Silber S, Windecker S, Serruys PW. Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. A fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: an optical coherence tomography substudy from the RESOLUTE All Comers trial. Eur Heart J. 2011;32:2454-2463. Doi: 10. 1093/eurheartj/ehr182.
32. Kim JS, Kim BK, Jang IK, Shin DH, Ko YG, Choi D, Hong MK, Cho YK, Nam CW, Hur SH, Choi JH, Song YB, Hahn JY, Choi SH, Gwon HC, Jang Y. ComparisOn of neointimal coVerage betwEen zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT). Am Heart J. 2012;163:601-607. Doi: 10. 1016/j. Ahj. 2011. 10. 016.
33. Kim S, Kim JS, Shin DH, Kim BK, Ko YG, Choi D, Cho YK, Nam CW, Hur SH, Jang Y, Hong MK. Comparison of early strut coverage between zotarolimus-and everolimus-eluting stents using optical coherence tomography. Am J Cardiol. 2013;111:1-5. Doi: 10. 1016/j. Amjcard. 2012. 08. 037.
34. Kedhi E, Stone GW, Kereiakes DJ, Serruys PW, Parise H, Fahy M, Simonton CA, Sudhir K, Sood P, Smits PC. Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials. EuroIntervention. 2012;8:599-606. Doi: 10. 4244/EIJV8I5A92.
35. Silber S, Kirtane AJ, Belardi JA, Liu M, Brar S, Rothman M, Windecker S. Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. Eur Heart J. 2014;35:1949-1956. Doi: 10. 1093/ eurheartj/ehu026.
36. Meredith IT, Verheye S, Weissman NJ, Barragan P, Scott D, Valdés Chávarri M, West NE, Kelbak H, Whitbourn R, Walters DL, Kubica J, Thuesen L, Masotti M, Banning A, Sjögren I, Stables RH, Allocco DJ, Dawkins KD. Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent. EuroIntervention. 2013;9:308-315. Doi: 10. 4244/EIJV9I3A52.
37. Pilgrim T, Heg D, Roffi M, Tüller D, Muller O, Vuilliomenet A, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Fahrni T, Moschovitis A, Noble S, Eberli FR, Wenaweser P, Jüni P, Windecker S. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimuseluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. Lancet. 2014;384:2111-2122. Doi: 10. 1016/S0140-6736(14)61038-2.
38. Saito S, Valdes-Chavarri M, Richardt G, Moreno R, Iniguez Romo A, Barbato E, Carrie D, Ando K, Merkely B, Kornowski R, Eltchaninoff H, James S, Wijns W; CENTURY II Investigators. A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimuseluting coronary stent system: the CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting Coronary Stent System in the Treatment of Patients with Coronary Artery Disease) trial. Eur Heart J. 2014;35:2021-2031. Doi: 10. 1093/eurheartj/ehu210.